Postprandial levels of GLP-1, GIP and glucagon after 2 years of weight loss with a Paleolithic diet: a randomised controlled trial in healthy obese women

被引:28
|
作者
Otten, Julia [1 ]
Ryberg, Mats [1 ]
Mellberg, Caroline [1 ]
Andersson, Tomas [1 ]
Chorell, Elin [1 ]
Lindahl, Bernt [1 ]
Larsson, Christel [2 ]
Holst, Jens Juul [3 ,4 ]
Olsson, Tommy [1 ]
机构
[1] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden
[2] Univ Gothenburg, Dept Food & Nutr & Sport Sci, Gothenburg, Sweden
[3] Univ Copenhagen, NNF Ctr Basal Metab Res, Copenhagen, Denmark
[4] Univ Copenhagen, Dept Biomed Sci, Copenhagen, Denmark
基金
瑞典研究理事会;
关键词
GASTRIC-INHIBITORY POLYPEPTIDE; PEPTIDE-1; RELEASE; INCRETIN HORMONE; ORAL GLUCOSE; RISK-FACTORS; INSULIN; FAT; MAINTENANCE; SECRETION; METABOLISM;
D O I
10.1530/EJE-19-0082
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To investigate how weight loss by different diets impacts postprandial levels of glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon. Methods: In this single-centre, parallel group 2-year trial, 70 healthy postmenopausal obese women were randomised to the Paleolithic diet or a healthy control diet based on Nordic Nutrition Recommendations. Both diets were without calorie restriction. The primary outcome was the change in fat mass. Here, secondary analyses on GLP-1, GIP and glucagon measured during an OGTT are described. Results: In the Paleolithic diet group, mean weight loss compared to baseline was 11% at 6 months and 10% at 24 months. In the control diet group, mean weight loss was 6% after 6 and 24 months (P = 0.0001 and P = 0.049 for the comparison between groups at 6 and 24 months respectively). Compared to baseline, the mean incremental area under the curve (iAUC) for GLP-1 increased by 34 and 45% after 6 and 24 months in the Paleolithic diet group and increased by 59% after 24 months in the control diet group. The mean iAUC for GIP increased only in the Paleolithic diet group. The area under the curve (AUC) for glucagon increased during the first 6 months in both groups. The fasting glucagon increase correlated with the beta-hydroxybutyrate increase. Conclusions: Weight loss caused an increase in postprandial GLP-1 levels and a further rise occurred during weight maintenance. Postprandial GIP levels increased only after the Paleolithic diet. Reduced postprandial glucagon suppression may be caused by a catabolic state.
引用
收藏
页码:417 / 427
页数:11
相关论文
共 50 条
  • [31] Effect of whey protein supplementation on levels of endocannabinoids and some of metabolic risk factors in obese women on a weight-loss diet: a study protocol for a randomized controlled trial
    Fatemeh Haidari
    Vahideh Aghamohammadi
    Majid Mohammadshahi
    Kambiz Ahmadi- Angali
    Nutrition Journal, 16
  • [32] Effect of whey protein supplementation on levels of endocannabinoids and some of metabolic risk factors in obese women on a weight-loss diet: a study protocol for a randomized controlled trial
    Haidari, Fatemeh
    Aghamohammadi, Vahideh
    Mohammadshahi, Majid
    Ahmadi-Angali, Kambiz
    NUTRITION JOURNAL, 2017, 16
  • [33] MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
    Ambery, Philip
    Parker, Victoria E.
    Stumvoll, Michael
    Posch, Maximilian G.
    Heise, Tim
    Plum-Moerschel, Leona
    Tsai, Lan-Feng
    Robertson, Darren
    Jain, Meena
    Petrone, Marcella
    Rondinone, Cristina
    Hirshberg, Boaz
    Jermutus, Lutz
    LANCET, 2018, 391 (10140): : 2607 - 2618
  • [34] The Effect of Antrum Size on Weight Loss, Glucagon-Like Peptide-1 (GLP-1) Levels, and Glycemic Control Following Laparoscopic Sleeve Gastrectomy in Adolescents with Obesity and Type 2 Diabetes
    Shehata, Mohamed A.
    Elhaddad, Ahmed
    El-Attar, Ashraf A.
    Shehata, Sherif M.
    OBESITY SURGERY, 2021, 31 (10) : 4376 - 4385
  • [35] The Effect of Antrum Size on Weight Loss, Glucagon-Like Peptide-1 (GLP-1) Levels, and Glycemic Control Following Laparoscopic Sleeve Gastrectomy in Adolescents with Obesity and Type 2 Diabetes
    Mohamed A. Shehata
    Ahmed Elhaddad
    Ashraf A. El-Attar
    Sherif M. Shehata
    Obesity Surgery, 2021, 31 : 4376 - 4385
  • [36] Robust glucose control and weight loss after 6 weeks of treatment with MEDI0382, a balanced GLP-1/Glucagon receptor dual agonist, in patients with type 2 diabetes
    Ambery, P.
    Stumvoll, M.
    Posch, M.
    Heise, T.
    Plum-Moerschel, L.
    Tsai, L. -F.
    Robertson, D.
    Petrone, M.
    Rondinone, C.
    Parker, V.
    Hirshberg, B.
    Jermutus, L.
    DIABETOLOGIA, 2018, 61 : S362 - S362
  • [37] Robust Glucose Control and Weight Loss after Six Weeks of Treatment with MEDI0382, a Balanced GLP-1/Glucagon Receptor Dual Agonist, in Patients with Type 2 Diabetes
    Ambery, Philip
    Stumvoll, Michael W.
    Posch, Maximilian G.
    Heise, Tim
    Plum-Moerschel, Leona
    Tsai, Lan-Feng
    Robertson, Darren
    Petrone, Marcella
    Rondinone, Cristina
    Parker, Victoria E.
    Hirshberg, Boaz
    Jermutus, Lutz
    DIABETES, 2018, 67
  • [38] The effects of sodium butyrate supplementation on the expression levels of PGC-1α, PPARα, and UCP-1 genes, serum level of GLP-1, metabolic parameters, and anthropometric indices in obese individuals on weight loss diet: a study protocol for a triple-blind, randomized, placebo-controlled clinical trial
    Amiri, Parichehr
    Hosseini, Seyed Ahmad
    Roshanravan, Neda
    Saghafi-Asl, Maryam
    Tootoonchian, Mitra
    TRIALS, 2023, 24 (01)
  • [39] The effects of sodium butyrate supplementation on the expression levels of PGC-1α, PPARα, and UCP-1 genes, serum level of GLP-1, metabolic parameters, and anthropometric indices in obese individuals on weight loss diet: a study protocol for a triple-blind, randomized, placebo-controlled clinical trial
    Parichehr Amiri
    Seyed Ahmad Hosseini
    Neda Roshanravan
    Maryam Saghafi-Asl
    Mitra Tootoonchian
    Trials, 24
  • [40] A randomized, double-blinded, placebo-controlled single ascending dose study to assess safety, tolerability, immunogenicity, and pharmacokinetics of a novel long-acting GLP-1/GIP/glucagon triple agonist (hm15211) in healthy obese subjects
    Choi, JaeDuk
    Kim, Youngmin
    Eun, Kahee
    Morrow, Linda
    Hompesch, Marcus
    Baek, Seungjae
    JOURNAL OF HEPATOLOGY, 2020, 73 : S455 - S456